Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Dendermonde – page 155

2 119 clinical trials in Dendermonde, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dendermonde at a glance
2 119
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 119 trials in Dendermonde

Open in trial search

Epilepsy

Not recruiting

Study on Clioquinol for Reducing Seizures in Patients with Drug-Resistant Epilepsy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Clioquinol
  • Sponsor:UZ Leuven

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Migraine

Not recruiting

Study on the Safety and Tolerability of Lasmiditan for Treating Migraine in Children Aged 6 to 17

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Lasmiditan
  • Sponsor:Eli Lilly & Co.

Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study Comparing Linvoseltamab to Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Safety and Effects of Fenfluramine in Infants Aged 1 to Less Than 2 Years with Dravet Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Dendermonde

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluating new therapeutic approaches for reducing cardiovascular risks.

  • Atherosclerotic cardiovascular disease prevention
  • Lipid management therapies
  • Cardiovascular risk reduction

Cutting-edge trials examining novel compounds for improving cardiovascular outcomes.

02 Cardiac Rhythm Disorders

Studies investigating treatments for atrial fibrillation and stroke prevention. Research comparing new anticoagulation therapies with established treatments for preventing systemic embolism.

  • Stroke prevention in AF
  • Novel anticoagulants
  • Cardioembolic event prevention

Advanced clinical research focusing on improving outcomes in cardiac rhythm management.

03 Specialized Cardiac Conditions

Research targeting rare cardiac conditions including transthyretin amyloidosis with cardiomyopathy. Evaluation of innovative treatments for specific cardiac pathologies.

  • Cardiomyopathy management
  • Rare cardiac diseases
  • Targeted therapeutic approaches

Focused studies on improving survival rates and quality of life in specialized cardiac conditions.

04 Stroke Management

Clinical trials examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Studies evaluating new therapeutic options for stroke prevention and management.

  • Post-stroke care
  • TIA management
  • Stroke prevention strategies

Development of advanced treatments for better stroke outcomes.

05 Oncology Research

Studies investigating the role of acetylsalicylic acid in improving survival rates for colon cancer patients. Research focused on preventing cancer recurrence after surgical intervention.

  • Colon cancer treatment
  • Post-surgical care
  • Cancer recurrence prevention

Innovative approaches in cancer survival improvement strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.